Status:
UNKNOWN
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
Lead Sponsor:
Jing Li
Collaborating Sponsors:
Nanjing Shihejiyin Technology, Inc.
Conditions:
Ovarian Cancer Stage IV
Ovarian Cancer Stage III
Eligibility:
FEMALE
18+ years
Brief Summary
Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. This study plans to use ctDNA dynamic monitorin...
Detailed Description
This study plans to include ovarian cancer patients who have undergone PDS/IDS surgery. By analyzing the surgical tissue samples of ovarian cancer patients, we aim to identify risk factors related to ...
Eligibility Criteria
Inclusion
- ≥ 18 years old.
- Patients diagnosed with stage IIIC-IVA ovarian cancer through pathological examination.
- The participant has read and fully understands the patient information, and has signed the informed consent form.
- The patient is willing to undergo primary debulking surgery (PDS) or interval debulking surgery（IDS）. -
Exclusion
- Other tumors have been detected within the last 5 years.
- Organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants.
- Patients was deemed unsuitable to participate in this study by other researchers.
- Patients who have previously received neoadjuvant chemotherapy or targeted therapy.
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06025045
Start Date
August 1 2022
End Date
August 1 2025
Last Update
September 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China